Bicycle Therapeutics (NASDAQ:BCYC) focuses on innovating biotherapeutics through its proprietary bicyclic peptide technology. The Cambridge, U.K.-based company strives to address unmet needs across oncology and other serious diseases with its novel approach. Bicycle's unique technology platform enables the rapid development of a new class of drugs, aiming to provide a combination of the precision of monoclonal antibodies with the pharmacological properties of small molecules. Its lead projects are geared towards creating transformative treatments for cancer and other severe diseases, highlighting a commitment to improving patient outcomes. The pursuit of groundbreaking discoveries in drug development is at the core of Bicycle's operations and objectives, emphasizing its dedication to advancing healthcare through innovation.